CLAIMS

1. A use of a compound that reduces the activity or expression of a Programmed Cell Death- 1 (PD-I) polypeptide in the manufacture of a medicament for the treatment of a symptom of a cancer in a subject, wherein the cancer is angio immunoblastic lymphoma or nodular lymphocyte predominant Hodgkin lymphoma, and wherein the compound is an anti-PD-1 antibody, an ant-PD-L1 antibody, an anti-PD-L2 antibody, an anti-PD-1 RNAi, an anti-PD-L1 RNAi, an anti-PD-L2 RNAi, an anti-PD-1 antisense RNA, an anti-PD-L1 antisense RNA, an anti-PD-L2 antisense RNA, a dominant negative PD-1 protein, a dominant negative PD-L1 protein, or a dominant negative PD-L2 protein.

2. The use of claim 1, wherein said compound reduces the activity of a PD-1 ligand (PD-L1) or a PD-1 ligand 2 (PD-L2).

3. The use of claim 1, wherein said compound reduces the interaction between PD-1 and PD-L1 or the interaction between PD-1 and PD-L2.

4. The use of claim 1, wherein said compound increases the cytotoxic T-cell activity in said subject.

5. The use of claim 4, wherein said cytotoxic T-cell activity is cytokine production, T cell proliferation, or infectious agent clearance.

6. The use of claim 5, wherein said T-cell is a cancer specific T-cell.

7. The use of claim 5, wherein said cytokine is IFNγ, TNFα, or IL-2.

8. The use of claim 1, wherein said anti-PD-1 antibody, an ant-PD-L1 antibody, or an anti-PD-L2 antibody is a monoclonal antibody, a

humanized antibody, a deimmunized antibody, or an Ig fusion protein.

9. The use of claim 1, further comprising administering to said subject a vaccine.

10. The use of claim 9, wherein said vaccine comprises an adjuvant or a prime booster shot.

11. The use of claim 1, further comprising administering to said subject a second compound.

12. The use of claim 11, wherein said second compound is, an anti-inflammatory compound, an antineoplastic compound or an analgesic.

13. The use of claim 11, wherein said second compound reduces the expression or activity of cytotoxic T lymphocyte antigen 4 (CTLA-4) or B and T lymphocyte attenuator (BTLA).

14. The use of claim 11, wherein said second compound reduces cancer cell volume.

15. The use of claim 11, wherein said second compound is an anti-CTLA-4 antibody, an anti-BTLA antibody, an anti-CD28 antibody, an anti-ICOS antibody, an anti- lCOS- L antibody, an anti-B7-1 antibody, an antl-B7-2 antibody, an anti-B7-H3 antibody, or an anti-B7-H4 antibody.

16. The use of claim 1, wherein said subject is a human.

17. A use of an antigen-specific T cell that has been contacted with a compound that reduces the expression or activity of a PD-1 polypeptide in said cell in the manufacture of a medicament for the treatment of a cancer in a

subject, wherein the cancer is angioimmunoblastic lymphoma or nodular lymphocyte predominant Hodgkin lymphoma.

18. The use of claim 17, wherein the subject is further administered an antigen.

CLAIMS

1. A use of a compound that reduces the activity or expression of a Programmed Cell Death- 1 (PD-1) polypeptide in the manufacture of a medicament for the treatment of a symptom of a lymphoproliferative cancer in a subject, wherein the cancer is a Hodgkin's lymphoma, an angio immunoblastic lymphoma or a nodular lymphocyte predominant Hodgkin's lymphoma, and wherein the compound is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-1 RNAi, an anti-PD-L1 RNAi, an anti-PD-1 antisense RNA, an anti-PD-L1 antisense RNA, a dominant negative PD-1 protein, or a dominant negative PD-L1 protein.

2. The use of claim 1, wherein said compound reduces the activity of a PD-1 ligand (PD-L1).

3. The use of claim 1, wherein said compound reduces the interaction between PD-1 and PD-L1.

4. The use of claim 1, wherein said compound increases the cytotoxic T-cell activity in said subject.

5. The use of claim 4, wherein said cytotoxic T-cell activity is cytokine production, T cell proliferation, or infectious agent clearance.

6. The use of claim 5, wherein said T-cell is a cancer specific T-cell.

7. The use of claim 5, wherein said cytokine is IFNγ, TNFα, or IL-2.

8. The use of claim 1, wherein said anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-PD-L2 antibody is a monoclonal antibody, a humanized antibody, a deimmunized antibody, or an Ig fusion protein.

9. The use of claim 1, further comprising administering to said subject a vaccine.

10. The use of claim 9, wherein said vaccine comprises an adjuvant or a prime booster shot.

11. The use of claim 1, further comprising administering to said subject a second compound.

12. The use of claim 11, wherein said second compound is, an anti-inflammatory compound, an antineoplastic compound or an analgesic.

13. The use of claim 11, wherein said second compound reduces the expression or activity of cytotoxic T lymphocyte antigen 4 (CTLA-4) or B and T lymphocyte attenuator (BTLA).

14. The use of claim 11, wherein said second compound reduces cancer cell volume.

15. The use of claim 11, wherein said second compound is an anti-CTLA-4 antibody, an anti-BTLA antibody, an anti-CD28 antibody, an anti-ICOS antibody, an anti- lCOS- L antibody, an anti-B7-1 antibody, an anti-B7-2 antibody, an anti-B7-H3 antibody, or an anti-B7-H4 antibody.

16. The use of claim 1, wherein said subject is a human.

17. A use of an antigen-specific T cell that has been contacted with a compound that reduces the expression or activity of a PD-1 polypeptide in said cell in the manufacture of a medicament for the treatment of a cancer in a subject, wherein the cancer is angioimmunoblastic lymphoma or nodular lymphocyte predominant Hodgkin lymphoma, wherein said compound is an anti-PD-1 antibody, an anti-PD-1 RNAi, an anti-PD-1 antisense RNA, or a dominant negative PD-1 protein.

18. The use of claim 17, wherein the subject is further administered an antigen.